Psychedelic medicine to better treat addiction
We are at a crisis point in the field of mental health provision and Addiction treatment
Mental health and addictions are the 5th leading cause of illness globally, affecting 20% of the global population. The global substance Addiction treatment industry is valued at US$17.5bn per annum and is forecast to increase to US$31.5bn per annum by 2027.
Unlike other medical disciplines, psychiatry focuses on maintenance rather than cure, and symptom suppression rather than addressing the root causes of these illnesses.
The exception is Psychedelics and Psychedelic-Assisted Psychotherapy which have the potential to radically change Addiction treatment and deliver significantly better patient outcomes.
Awakn Life Sciences is a publicly traded (NEO: AWKN) (OTCQB: AWKNF) biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction.
Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally.
Clear IP development pathway
• Psychedelic drug discovery targeting Addiction
• Psychedelic therapy development targeting Addiction
• Enabling technologies & predictive analytics
Multiple revenue streams:
• Clinic revenue starting in 2021.
• Licencing Partnership revenue starting in 2022.
• Drug discovery revenue in 2028+.
Geographic focus for Clinics:
Unique focus on and first mover advantage in the UK and EU, with a combined population of 400m people and GDP per annum = US$20trn
The leading scientific and medical team in the industry:
Prof. David Nutt, Dr. Ben Sessa, Prof. Celia Morgan,, Dr. Michael Mithoefer, Ann Mithoefer, and Prof. Matt Johnson.
Global research leaders in the field of psychedelic treatments for Addiction:
Dr. Ben Sessa led the world’s only MDMA-Assisted Psychotherapy and AUD study (BIMA) and Prof. Celia Morgan led the world’s only Ketamine-Assisted Psychotherapy AUD study (KARE).
Strategic partnerships with two leading UK universities
for exclusive access to data and findings from recent clinics trials.
15% - 20%
This is the percentage of the population in the US, EU, UK & Canada that are affected by Addiction.
The global substance Addiction treatment industry is valued at US$17.5bn per annum and is forecast to increase to US$31.5bn per annum by 2027.
US and EU
North America accounts for 40% of this market, Europe 30%, Rest of World 30%.
5% of the global population suffer from Alcohol Use Disorder (AUD), however it accounts for 30% of the treatment market.
Sign Up for Newsletter: